About Supha Pharmachem Limited
Data last updated:
Supha Pharmachem Limited is a public limited company based in Mumbai, Maharashtra, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 19 February 1988.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24100MH1988PLC343805. Its GSTIN is 27AABCR4409G1ZJ (Maharashtra). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 539561.
The company has an authorised share capital of ₹110 Cr and a paid-up capital of ₹88.2 Cr. It was formerly known as Roxy Exports Limited. It is led by directors including Vignesh Laxman Gawde (Whole-Time Director) and Rambhajan Vishwakarma.
Its last annual general meeting (AGM) was held on 24 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the latest consolidated financials for FY 2024-25, the company reported a revenue of ₹405.25 Cr. For the same year it recorded a net profit of ₹2.14 Cr (net margin 0.5%) and EBITDA of ₹1.27 Cr (EBITDA margin 0.3%). The net worth stands at ₹43.89 Cr. Total assets are valued at ₹1,185.28 Cr.
The company has about 6 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Remedium Lifecare and Roxy Exports. As per MCA filings, the company has satisfied charges of ₹3.26 Cr on record. Court records list 13 cases involving the company, including 8 filed by the company and 5 filed against it; 2 cases are pending. The company has 130 deals on record (128 market trades, 1 rights issue, 1 secondary share transfer); the latest was in June 2026. Its 8 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 5 smaller; the largest is Super Specialities Pharma Warehousing & Logistics Private Limited with revenue of ₹241.91 Cr. The company has 2 MSME Form 1 returns on record between 2022 and 2023, listing 3 overdue payments to 3 micro and small suppliers.
The last known website on record is remediumlifecare.com.
Company details
Name history
Supha Pharmachem has undergone 2 name changes throughout its history. The company was previously known as Roxy Exports Limited, and Supha Pharmachem Limited. The current legal name is Supha Pharmachem Limited.
| Company Name | Status |
|---|---|
| Supha Pharmachem Limited | Current |
| Roxy Exports Limited | Previous |
CIN history
Supha Pharmachem has 4 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100MH1988PLC343805, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100MH1988PLC343805 | Current |
| L51909PB1988PLC008009 | Previous |
| L29100MH1988PLC343805 | Previous |
| U51909PB1988PLC008009 | Previous |
| L29100PB1988PLC008009 | Previous |
Contact details
Supha Pharmachem Limited's registered office is in Mumbai, Maharashtra. Its website is remediumlifecare.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressOffice No.9 K Raheja Prime Marol Industrial Estate, Behind Ravi Vihar Hotel Sagbaug Road Marol Andheri East, Mumbai, Maharashtra, India – 400059
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Supha Pharmachem Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Supha Pharmachem operates two associated brands: Remedium Lifecare and Roxy Exports. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Trading of pharmaceutical APIs and intermediates is conducted in domestic and international markets. | remediumlifecare.com | |
| Solutions for generating water from atmospheric air are provided. | roxyexports.in |
Business activity
The main business activity of Supha Pharmachem is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Supha Pharmachem Limited, buy the company report.
Financials of Supha Pharmachem Limited
FY 2024-25 filings availableSupha Pharmachem Limited reported revenue of ₹405.25 Cr for FY 2024-25.
Financial Highlights
FY 2024-25 · ConsolidatedFinancial summary ₹ Cr
| Metrics | FY 2024-25 |
|---|---|
| Income statement | |
| Revenue | 405 |
| EBITDA | 1.27 |
| EBITDA margin | +0.3% |
| Profit before tax | 4.39 |
| Net profit | 2.14 |
| Net profit margin | +0.5% |
| EPS (₹) | 0.05 |
| Balance sheet | |
| Total assets | 1,185 |
| Net worth | 43.89 |
| Total debt | 1,141 |
| Cash & bank | 1.43 |
| Net working capital | 1,185 |
| Cash flow | |
| Cash from operations | (1,135) |
| Cash from investing | 0.13 |
| Cash from financing | 1,136 |
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | 111 | 113 | 264 |
| Other income | 3.25 | 3.48 | 0.66 |
| EBITDA | 7.37 | 1.87 | (0.46) |
| EBITDA margin | +6.6% | +1.6% | -0.2% |
| Depreciation | 0.00 | 0.00 | 0.01 |
| Interest | 0.19 | (0.36) | 1.59 |
| Profit before tax | 10.43 | 5.71 | (1.40) |
| Tax | 1.81 | 1.06 | 0.64 |
| Net profit | 8.62 | 4.65 | (2.04) |
| EPS (₹) | 0.10 | 0.05 | (0.05) |
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 222 | 4,042 | 510 | 505 | 90.03 | 2.89 | 0.16 |
| Revenue growth | -94.5% | +692.7% | +1.0% | +460.7% | +3015.2% | +1706.3% | - |
| EBITDA | 0.54 | 34.22 | 8.02 | 1.83 | 0.73 | 0.40 | (0.07) |
| EBITDA margin | +0.2% | +0.9% | +1.6% | +0.4% | +0.8% | +13.8% | -43.8% |
| Profit before tax | 3.66 | 50.46 | 7.42 | 1.53 | 0.65 | 0.38 | 0.02 |
| Net profit | 1.53 | 32.74 | 5.45 | 1.08 | 0.48 | 0.29 | 0.00 |
| Net profit margin | +0.7% | +0.8% | +1.1% | +0.2% | +0.5% | +10.0% | 0.0% |
| EPS (₹) | 0.04 | 32.47 | 15.07 | 2.99 | 1.33 | 0.77 | 0.02 |
| Balance sheet | |||||||
| Total assets | 1,185 | 101 | 10.36 | 4.94 | 14.36 | 3.72 | 3.15 |
| Net worth | 43.30 | 42.96 | 10.36 | 4.94 | 3.86 | 3.35 | 3.08 |
| Total debt | 1,141 | 57.70 | 0.00 | 0.00 | 10.50 | 0.36 | 0.08 |
| Cash & bank | 1.36 | 1.52 | 21.86 | 1.44 | 0.81 | 0.93 | 1.08 |
| Net working capital | 1,185 | 101 | 10.27 | 4.76 | 14.15 | 3.49 | 3.16 |
| Cash flow | |||||||
| Cash from operations | (1,079) | (74.16) | 20.50 | 11.28 | (10.21) | (0.20) | (0.07) |
| Cash from investing | 0.06 | 0.00 | (0.04) | (0.05) | (0.04) | (0.24) | 1.06 |
| Cash from financing | 1,078 | 53.83 | (0.04) | (10.61) | 10.14 | 0.29 | 0.08 |
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.58 | 18.37 | 81.57 | 38.15 | 25.08 | 77.70 | 1,408 | 1,834 |
| Revenue growth (YoY) | -65.8% | -76.4% | -94.2% | -97.9% | -94.7% | - | - | - |
| Other income | 3.25 | 3.48 | 0.66 | 7.43 | 0.82 | 1.89 | 2.89 | 14.12 |
| Total expenses | 11.57 | 22.58 | 82.75 | 43.63 | 20.62 | 77.31 | 1,444 | 1,779 |
| EBITDA | (2.99) | (4.21) | (1.18) | (5.48) | 4.46 | 0.39 | (35.03) | 54.70 |
| EBITDA margin | -34.8% | -22.9% | -1.4% | -14.4% | +17.8% | +0.5% | -2.5% | +3.0% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest | 0.19 | (0.36) | 1.59 | 0.88 | 2.81 | 0.00 | 3.85 | 0.03 |
| Profit before tax | 0.07 | (0.37) | (2.12) | 1.06 | 2.46 | 2.27 | (36.00) | 68.78 |
| Tax | 0.00 | 0.00 | 0.52 | 0.29 | 0.68 | 0.63 | 17.72 | 22.96 |
Financial Statements
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | 111 | 113 | 264 |
| Other income | 3.25 | 3.48 | 0.66 |
| EBITDA | 7.37 | 1.87 | (0.46) |
| EBITDA margin | +6.6% | +1.6% | -0.2% |
| Depreciation | 0.00 | 0.00 | 0.01 |
| Interest | 0.19 | (0.36) | 1.59 |
| Profit before tax | 10.43 | 5.71 | (1.40) |
| Tax | 1.81 | 1.06 | 0.64 |
| Net profit | 8.62 | 4.65 | (2.04) |
| EPS (₹) | 0.10 | 0.05 | (0.05) |
| Particulars | FY 2024-25 |
|---|---|
| Revenue | 405 |
| Other income | 10.80 |
| Total expenses | 404 |
| Employee cost | 0.41 |
| EBITDA | 1.27 |
| EBITDA margin | +0.3% |
| Depreciation | 0.04 |
| Interest | 7.64 |
| Profit before tax | 4.39 |
| Tax | 2.25 |
| Net profit | 2.14 |
| Net profit margin | +0.5% |
| EPS (₹) | 0.05 |
| Particulars | FY 2024-25 |
|---|---|
| Equity & liabilities | |
| Share capital | 40.32 |
| Reserves & surplus | 3.57 |
| Shareholders' funds (net worth) | 43.89 |
| Minority interest | 0.00 |
| Secured loans | 1.54 |
| Unsecured loans | 1,140 |
| Total debt | 1,141 |
| Total liabilities | 1,185 |
| Assets | |
| Gross block | 0.22 |
| Net block | 0.01 |
| Capital work in progress | 0.00 |
| Investments | 0.00 |
| Inventories | 269 |
| Sundry debtors | 772 |
| Cash & bank balances | 1.43 |
| Loans & advances | 678 |
| Total current assets | 1,720 |
| Total current liabilities | 535 |
| Net working capital | 1,185 |
| Total assets | 1,185 |
| Particulars | FY 2024-25 |
|---|---|
| Opening cash | 0.00 |
| Net cash from operating activities | (1,135) |
| Net cash from investing activities | 0.13 |
| Net cash from financing activities | 1,136 |
| Net change in cash | 1.43 |
| Closing cash | 1.43 |
| Particulars | FY 2024-25 |
|---|---|
| Growth | |
| PBT growth | +9997.0% |
| Profitability & leverage | |
| Net income margin | +0.5% |
| Return on capital employed | +1.0% |
| Return on net worth | +4.9% |
| Debt / equity | 26.01 |
| Long-term debt / equity | 0.00 |
| Interest cover | 621.14 |
| Efficiency & per share | |
| Fixed asset turnover | 1,842.05 |
| Inventory turnover | 1.50 |
| Debtors turnover | 0.53 |
| EPS (₹) | 0.05 |
| Dividend per share (₹) | 0.00 |
| Book value per share (₹) | 1.09 |
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.58 | 18.37 | 81.57 | 38.15 | 25.08 | 77.70 | 1,408 | 1,834 |
| Revenue growth (YoY) | -65.8% | -76.4% | -94.2% | -97.9% | -94.7% | - | - | - |
| Other income | 3.25 | 3.48 | 0.66 | 7.43 | 0.82 | 1.89 | 2.89 | 14.12 |
| Total expenses | 11.57 | 22.58 | 82.75 | 43.63 | 20.62 | 77.31 | 1,444 | 1,779 |
| EBITDA | (2.99) | (4.21) | (1.18) | (5.48) | 4.46 | 0.39 | (35.03) | 54.70 |
| EBITDA margin | -34.8% | -22.9% | -1.4% | -14.4% | +17.8% | +0.5% | -2.5% | +3.0% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest | 0.19 | (0.36) | 1.59 | 0.88 | 2.81 | 0.00 | 3.85 | 0.03 |
| Profit before tax | 0.07 | (0.37) | (2.12) | 1.06 | 2.46 | 2.27 | (36.00) | 68.78 |
| Tax | 0.00 | 0.00 | 0.52 | 0.29 | 0.68 | 0.63 | 17.72 | 22.96 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Revenue | 222 | 4,042 | 510 | 505 | 90.03 | 2.89 | 0.16 |
| Revenue growth | -94.5% | +692.7% | +1.0% | +460.7% | +3015.2% | +1706.3% | - |
| Other income | 10.80 | 21.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 |
| Total expenses | 222 | 4,007 | 502 | 503 | 89.30 | 2.49 | 0.23 |
| Employee cost | 0.41 | 0.40 | 0.55 | 0.21 | 0.19 | 0.18 | 0.04 |
| EBITDA | 0.54 | 34.22 | 8.02 | 1.83 | 0.73 | 0.40 | (0.07) |
| EBITDA margin | +0.2% | +0.9% | +1.6% | +0.4% | +0.8% | +13.8% | -43.8% |
| Depreciation | 0.04 | 0.06 | 0.15 | 0.07 | 0.06 | 0.01 | 0.00 |
| Interest | 7.64 | 4.78 | 0.45 | 0.23 | 0.02 | 0.01 | 0.00 |
| Profit before tax | 3.66 | 50.46 | 7.42 | 1.53 | 0.65 | 0.38 | 0.02 |
| Tax | 2.13 | 17.72 | 1.97 | 0.45 | 0.17 | 0.09 | 0.02 |
| Net profit | 1.53 | 32.74 | 5.45 | 1.08 | 0.48 | 0.29 | 0.00 |
| Net profit margin | +0.7% | +0.8% | +1.1% | +0.2% | +0.5% | +10.0% | 0.0% |
| EPS (₹) | 0.04 | 32.47 | 15.07 | 2.99 | 1.33 | 0.77 | 0.02 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 40.32 | 10.08 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 |
| Reserves & surplus | 2.98 | 32.88 | 6.76 | 1.34 | 0.26 | (0.25) | (0.52) |
| Shareholders' funds (net worth) | 43.30 | 42.96 | 10.36 | 4.94 | 3.86 | 3.35 | 3.08 |
| Secured loans | 1.54 | 1.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 1,140 | 56.38 | 0.00 | 0.00 | 10.50 | 0.36 | 0.08 |
| Total debt | 1,141 | 57.70 | 0.00 | 0.00 | 10.50 | 0.36 | 0.08 |
| Total liabilities | 1,185 | 101 | 10.36 | 4.94 | 14.36 | 3.72 | 3.15 |
| Assets | |||||||
| Gross block | 0.22 | 0.22 | 0.20 | 0.34 | 0.29 | 0.24 | 0.00 |
| Net block | 0.01 | 0.04 | 0.08 | 0.19 | 0.21 | 0.23 | 0.00 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 269 | 133 | 7.32 | 83.87 | 3.11 | 0.70 | 0.20 |
| Sundry debtors | 591 | 921 | 172 | 64.00 | 23.68 | 1.50 | 0.14 |
| Cash & bank balances | 1.36 | 1.52 | 21.86 | 1.44 | 0.81 | 0.93 | 1.08 |
| Loans & advances | 678 | 892 | 953 | 74.27 | 10.72 | 0.91 | 2.11 |
| Total current assets | 1,540 | 1,948 | 1,154 | 224 | 38.32 | 4.04 | 3.53 |
| Total current liabilities | 355 | 1,847 | 1,144 | 219 | 24.17 | 0.55 | 0.37 |
| Net working capital | 1,185 | 101 | 10.27 | 4.76 | 14.15 | 3.49 | 3.16 |
| Total assets | 1,185 | 101 | 10.36 | 4.94 | 14.36 | 3.72 | 3.15 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.52 | 21.86 | 1.44 | 0.81 | 0.93 | 1.08 | 0.02 |
| Net cash from operating activities | (1,079) | (74.16) | 20.50 | 11.28 | (10.21) | (0.20) | (0.07) |
| Net cash from investing activities | 0.06 | 0.00 | (0.04) | (0.05) | (0.04) | (0.24) | 1.06 |
| Net cash from financing activities | 1,078 | 53.83 | (0.04) | (10.61) | 10.14 | 0.29 | 0.08 |
| Net change in cash | (0.16) | (20.33) | 20.42 | 0.62 | (0.11) | (0.15) | 1.06 |
| Closing cash | 1.36 | 1.52 | 21.86 | 1.44 | 0.81 | 0.93 | 1.08 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -94.5% | +692.7% | +1.0% | +460.7% | +3015.2% | +1706.3% | - |
| EBITDA growth | -98.4% | +326.7% | +338.3% | +150.7% | +82.5% | +671.4% | - |
| PBT growth | -92.8% | +580.1% | +385.0% | +135.4% | +71.1% | +1800.0% | 0.0% |
| Net income growth | -95.3% | +500.7% | +404.6% | +125.0% | +65.5% | - | - |
| Revenue CAGR (3Y) | -23.9% | +255.4% | +460.9% | +1366.7% | +536.0% | +29.5% | -65.6% |
| EBITDA CAGR (3Y) | -33.4% | +260.6% | +171.7% | - | - | - | -38.4% |
| Profitability & leverage | |||||||
| Net income margin | +0.7% | +0.8% | +1.1% | +0.2% | +0.5% | +10.0% | 0.0% |
| Return on capital employed | +1.8% | +99.5% | +102.6% | +18.2% | +7.2% | +9.7% | +0.5% |
| Return on net worth | +3.6% | +122.8% | +71.0% | +24.6% | +12.5% | +7.3% | +0.3% |
| Debt / equity | 13.90 | 1.08 | 0.00 | 1.19 | 1.51 | 0.07 | 0.01 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 1.19 | 1.51 | 0.07 | 0.01 |
| Interest cover | 1,528.00 | 13.99 | 5.72 | 13.07 | 2.99 | 2.56 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1,011.36 | 19,246.24 | 1,888.30 | 1,602.51 | 339.74 | 24.08 | 1.52 |
| Inventory turnover | 1.11 | 57.51 | 11.18 | 11.61 | 47.26 | 6.42 | 1.60 |
| Debtors turnover | 0.29 | 7.40 | 4.31 | 11.51 | 7.15 | 3.52 | 0.15 |
| EPS (₹) | 0.04 | 32.47 | 15.07 | 2.99 | 1.33 | 0.77 | 0.02 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.07 | 42.62 | 28.79 | 13.72 | 10.72 | 9.32 | 8.55 |
To see the full year-wise statements and ratios of Supha Pharmachem Limited, buy the company report.
Board of directors of Supha Pharmachem Limited
Supha Pharmachem has 6 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vignesh Laxman Gawde | Whole-Time Director | 31 Oct 2025 | 0 Years 11 Months | As last reported |
| Rambhajan Vishwakarma | Director | 31 Oct 2025 | 0 Years 11 Months | As last reported |
| Vijay Pal Singh Gulya | Director | 30 May 2025 | 1 Years 4 Months | As last reported |
| Bikram Kumar Mund Also directs: True Value Propmart Private Limited, Carvan Builders Private Limited, Indiacraft Overseas Private Limited and 1 more | Director | 30 May 2025 | 1 Years 4 Months | As last reported |
| Shamim Adil Michal | Director | 22 Jan 2025 | 1 Years 9 Months | As last reported |
| Adarsh Deepak Munjal Also directs: Risevertise Media LLP | Director | 05 Sep 2023 | 3 Years 1 Months | As last reported |
Peer comparison
Supha Pharmachem Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Supha Pharmachem Limitedthis company | ₹405.25 Cr (FY 2025) | ₹2.14 Cr | 0.5% | 6 | Mumbai, Maharashtra, India | |
| Super Specialities Pharma Warehousing & Logistics Private Limited | ₹241.91 Cr (FY 2025) | 28.0% | Mumbai, Maharashtra, India | |||
| Generica India Limited | ₹235.66 Cr (FY 2025) | 14.0% | New Delhi, Delhi, India | |||
| Medihauxe International Private Limited | ₹235.12 Cr (FY 2023) | 9.0% | Hyderabad, Telangana, India | |||
| Chethana Pharma Private Limited | ₹232.09 Cr (FY 2025) | 10.0% | Davanagere, Karnataka, India | |||
| Chirag Medicare Solutions Private Limited | ₹231.02 Cr (FY 2025) | 9.0% | Davanagere, Karnataka, India | |||
| Curatio Health Care (I) Private Limited | ₹230.93 Cr (FY 2022) | 26.0% | Ahmedabad, Gujarat, India | |||
| Tancom Electronics Private Limited | ₹230.72 Cr (FY 2025) | 84.0% | Mumbai, Maharashtra, India | |||
| Getwell Medicare Solution Private Limited | ₹225.29 Cr (FY 2025) | 23.0% | Ernakulam, Kerala, India |
To see the full peer comparison of Supha Pharmachem Limited, buy the company report.
Auditor
Supha Pharmachem Limited is audited by TAORI SANDEEP & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| TAORI SANDEEP & ASSOCIATES | FY 2023 | 007414C |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 1.10%, foreign institutional investors hold 1.70%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 97.20%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 1.10% | 1.10% | 1.10% | 1.10% |
| Public | 98.90% | 98.90% | 98.90% | 98.90% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 09 Mar 2012 | 10345215 | Indian Overseas Bank | ₹95 Lakh | Satisfied | |
| 07 Jan 2011 | 10267820 | Indian Overseas Bank | ₹1.5 Cr | Satisfied | |
| 20 Feb 1996 | 90177673 | Punjab National Bank | ₹6 Lakh | Satisfied | |
| 02 Aug 1995 | 90180065 | Punjab National Bank | ₹2.5 Lakh | Satisfied | |
| 24 Apr 1995 | 90179632 | Punjab National Bank | ₹15 Lakh | Satisfied |
To see the full charge records of Supha Pharmachem Limited, buy the company report.
Total charge records: 14 View all charges
Deals & funding
Supha Pharmachem Limited has 130 deals on record (128 market trades, 1 rights issue, 1 secondary share transfer); the latest was in June 2026.
Deals on record (5 of 130)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2026 | Market trade | ₹29.8 Lakh | Seller: L7 Hitech Private Limited |
| Mar 2026 | Market trade | ₹82.1 Lakh | Buyer: Share India Securities Limited, Ishaan Tradefin LLP , an individual Seller: Share India Securities Limited, Ishaan Tradefin LLP |
| Mar 2026 | Market trade | ₹22.5 Lakh | Seller: L7 Hitech Private Limited |
| Mar 2026 | Market trade | ₹22.8 Lakh | Seller: Ishaan Tradefin LLP |
| Mar 2026 | Market trade | ₹2.88 Cr | Buyer: Devi Traders LLP , Ishaan Tradefin LLP , L7 Hitech Private Limited Seller: Devi Traders LLP , Comfort Capital Private Limited , 2 individuals |
To see the full deal history of Supha Pharmachem Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Supha Pharmachem Limited has 13 court cases on record: 8 filed by Supha Pharmachem, 5 filed against it. 2 cases are pending and 11 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 8 | 5 | 2 |
| High courts | 5 | 0 | 0 |
Cases on record (5 of 13)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S. Biocon Limited | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S. Biocon Limited | Disposed |
| District court, MYSURU, Karnataka | Court case (Com.O.S.) | Filed against the company by an individual | Pending |
| Bombay High Court | Writ petition | Filed by the company against The Deputy Commissioner of State Tax (SGST) and Anr | Disposed |
| District court, Ludhiana, Punjab | Civil suit | Filed by the company against Punjab State | Disposed |
To see the full case history of Supha Pharmachem Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Supha Pharmachem Limited has 2 MSME Form 1 returns on record between 2022 and 2023, listing 3 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (3 of 3)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Sanjog Communication Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Supha Pharmachem Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Supha Pharmachem Limited has a workforce of 6 employees on its EPFO records as of Mar 29, 2024, across 1 active EPFO establishment.
GST
Supha Pharmachem has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCR4409G1ZJ | Maharashtra | Active | 09 Jan 2019 |
To see the full GST registrations and return filing status of Supha Pharmachem Limited, buy the company report.
Recent activity
Supha Pharmachem Limited has 46 board changes on record since 2007: 26 appointments and 20 cessations. The latest: Rambhajan Vishwakarma was appointed as Director on 31 Oct 2025.
74 earlier events are in the company report.
News
Frequently asked questions
Supha Pharmachem is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Supha Pharmachem is a company under insolvency, formerly operating as a public limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 19 February 1988 and is registered under CIN L24100MH1988PLC343805. Listed on BSE: 539561. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Supha Pharmachem reported revenue of ₹405.25 Cr for FY 2024-25 based on consolidated financials.
Supha Pharmachem has 6 current directors:
- Vignesh Laxman Gawde - Whole-Time Director
- Rambhajan Vishwakarma - Director
- Vijay Pal Singh Gulya - Director
- Bikram Kumar Mund - Director
- Shamim Adil Michal - Director
- Adarsh Deepak Munjal - Director
The latest financial statements of Supha Pharmachem on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 24 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Supha Pharmachem is L24100MH1988PLC343805. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Supha Pharmachem is a listed company as per MCA records. Its shares are listed on BSE (code: 539561).
Supha Pharmachem has no open charges and satisfied charges of ₹3.26 Cr as per latest MCA filings.
Supha Pharmachem has 13 court cases on record: 8 filed by the company and 5 filed against it. 2 are pending. Most are in the district courts.
Supha Pharmachem was incorporated on 19 February 1988. It is registered with the Registrar of Companies, Mumbai.
Supha Pharmachem has 130 deals on record (128 market trades, 1 rights issue, 1 secondary share transfer); the latest was in June 2026.
The peers of Supha Pharmachem by revenue are Super Specialities Pharma Warehousing & Logistics Private Limited, Generica India Limited, Medihauxe International Private Limited, Chethana Pharma Private Limited, Chirag Medicare Solutions Private Limited and 3 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).